Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Clinical-stage biotechnology company developing next-generation antibody therapeutics. The company focuses on producing multi-antibody therapeutic formats to enable combination therapy in a single drug product, with capabilities spanning antibody engineering, cell-line and bioprocess development, analytical characterization, and CMC/regulatory activities. Programs include oncology, immuno-oncology, inflammation, infectious and metabolic disease areas.
Industries
Nr. of Employees
small (1-50)
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Bothell, Washington, United States, North America
Products
Dual-antibody production platform
Platform enabling the production of two distinct monoclonal antibodies as a single drug product, designed to combine multi-pathway therapeutic activity while simplifying administration and reducing cost versus separate antibody cocktails.
Bispecific antibody production platform
Platform for generating stable heterodimeric bispecific antibodies suited for expression and purification using standard antibody production methods.
Dual-antibody production platform
Platform enabling the production of two distinct monoclonal antibodies as a single drug product, designed to combine multi-pathway therapeutic activity while simplifying administration and reducing cost versus separate antibody cocktails.
Bispecific antibody production platform
Platform for generating stable heterodimeric bispecific antibodies suited for expression and purification using standard antibody production methods.
Expertise Areas
- Antibody therapeutics and combination antibody formats
- Antibody engineering and protein design
- Cell-line and bioprocess development
- Protein analytical characterization and mass spectrometry
Key Technologies
- Dual-antibody production from a single cell line
- Heterodimeric bispecific antibody production
- Mass spectrometry-based protein characterization
- HPLC, CE-SDS, and iCIEF analytical separations